Calendario de promoción Taysha Gene Therapies, Inc.
Horario avanzado
gráfico sencillo
Acerca de la empresa
Компания Taysha Gene Therapies, Inc., занимающаяся генной терапией, специализируется на разработке и коммерциализации генной терапии на основе аденоассоциированных вирусов для лечения моногенных заболеваний центральной нервной системы. В первую очередь он разрабатывает TSHA-101 для лечения ганглиозидоза GM2; TSHA-118 для лечения болезни CLN1; и TSHA-102 для лечения синдрома Ретта. Taysha Gene Therapies, Inc.
Más detalles| EV/EBITDA | -3.89 |
|---|---|
| EBITDA | -0.0011 |
| Цена ао | 2.29 |
| Сайт | http://www.tayshagtx.com |
| P/BV | 1.93 |
| Число акций ао | 0.11612 млрд |
| Див.доход ао | 0 |
| ISIN | US8776191061 |
| P/S | 39.7 |
| Выручка | 0.0025 |
| Валюта | usd |
| IPO date | 2020-09-24 |
| Sector | Health Care |
| Industry | Biotechnology |
| Валюта отчета | usd |
| Cambio de precio por día: | +1.52% (1.98) |
|---|---|
| Cambio de precio por semana.: | 0% (2.01) |
| Cambio de precio por mes: | -8.22% (2.19) |
| Cambio de precio en 3 meses.: | -17.62% (2.44) |
| Cambio de precio en seis meses: | -21.94% (2.575) |
| Cambio de precio por año: | -12.42% (2.295) |
| Cambio de precio en 3 años.: | -85.58% (13.94) |
| Cambio de precio desde principios de año.: | +10.74% (1.815) |
|
|
Subestimación
|
Eficiencia
|
|||||||||||||||||||||||||||||||||||||
Dividendos
|
Deber
|
Impulso de crecimiento
|
|||||||||||||||||||||||||||||||||||||
| Instituciones | Volumen | Compartir, % |
|---|---|---|
| FMR, LLC | 22439124 | 12 |
| RA Capital Management, L.P. | 18472503 | 9.88 |
| RTW Investments LP | 16893185 | 9.03 |
| VR Adviser, LLC | 10412872 | 5.57 |
| Vanguard Group Inc | 6195567 | 3.31 |
| Avoro Capital Advisors LLC | 4355555 | 2.33 |
| Baker Brothers Advisors, LLC | 4004756 | 2.14 |
| Eversept Partners, LP | 3780714 | 2.02 |
| Tybourne Capital Management (HK) Limited | 3700000 | 1.98 |
| Artal Group S.A. | 3663104 | 1.96 |
| ETF | Compartir, % | Rentabilidad del año, % | Dividendos, % |
|---|---|---|---|
| Virtus LifeSci Biotech Clinical Trials ETF | 0.40834 | 63.040315712071 | 0.33 |
| ProShares Ultra Nasdaq Biotechnology | 0.02673 | 51.697637072723 | 0.85651 |
| Goldman Sachs ActiveBeta US Small Cap Equity ETF | 0.02925 | 31.359936575053 | 1.41955 |
| ProShares Hedge Replication ETF | 0.0021 | 5.9237999659878 | 1.47892 |
| Invesco Nasdaq Biotechnology ETF | 0.03944 | 28.578975171685 | 0.8565 |
| iShares Neuroscience and Healthcare ETF | 0.6323 | 19.720292847757 | 0.03 |
| iShares Micro-Cap ETF | 0.0939 | 34.327031588619 | 1.54048 |
| iShares Russell 2000 Growth ETF | 0.02724 | 38.042556988 | 0.6026 |
| iShares Russell 3000 ETF | 0.001 | 31.230028873917 | 1.43482 |
| Invesco Dorsey Wright Healthcare Momentum ETF | 0.45001 | 43.183192261185 | 0.12263 |
| ProShares UltraPro Russell2000 | 0.00743 | 89.821266282945 | 1.47873 |
| Vanguard Russell 3000 ETF | 0 | 31.87314172448 | 1.43817 |
| Vanguard Russell 2000 Growth ETF | 0.03 | 37.361289927043 | 0.60264 |
| Vanguard Russell 2000 ETF | 0.01 | 32.773459189339 | 1.48801 |
| Principal Healthcare Innovators ETF | 0.04503 | 618.4964157054 | 0.8416 |
| Future Tech ETF | 0.04503 | 426.33969118983 | 0.8416 |
| Supervisor | Título profesional | Pago | año de nacimiento |
|---|---|---|---|
| Mr. Kamran Alam CPA, M.B.A. | CFO & Corporate Secretary | 703.61k | 1978 (46 años) |
| Ms. Emily McGinnis M.P.H. | Chief Patient & External Affairs Officer and Endpoint & Outcome Development Lead | N/A | |
| Mr. Frederick Porter Ph.D. | Chief of Staff & Technical Operations Officer | N/A | |
| Mr. Sean P. Nolan | CEO & Chairman | 674k | 1968 (56 años) |
| Dr. Sukumar Nagendran M.D. | President, Head of Research & Development and Director | 619.1k | 1967 (57 años) |
| Mr. Sean McAuliffe | Chief Business Officer | N/A | |
| Berge Minassian M.D. | Chief Medical Advisor of UT Southwestern Gene Therapy Program | N/A | |
| Ms. Tracy M. Porter SPHR | Chief People Officer | N/A | |
| Dr. Steven Gray Ph.D. | Chief Scientific Advisor of UT Southwestern Gene Therapy Program | N/A | |
| Hayleigh Collins | Director of Corporate Communications & Investor Relations | N/A |
DIRECCIÓN: United States, Dallas, TX , 3000 Pegasus Park Drive - abrir en mapas de google, abrir mapas de Yandex
Sitio web: http://www.tayshagtx.com
Sitio web: http://www.tayshagtx.com
